Biotech clinical-stage company Algernon Pharmaceuticals Inc. (OTCQB:AGNPF) has closed its previously announced non-brokered private placement for a total of 373,900 of its units at $3.75 per share, for gross proceeds of $1,402,125.
Algernon focuses on investigating new disease applications for already-approved drugs, including naturally occurring compounds, while specifically researching compounds that have never been approved in the U.S. or Europe to avoid off-label prescription writing.
